<DOC>
	<DOCNO>NCT01634087</DOCNO>
	<brief_summary>This study INCB039110 patient chronic plaque psoriasis . This study evaluate safety efficacy parameter INCB039110 .</brief_summary>
	<brief_title>A Study Escalating Doses INCB039110 Administered Orally Patients With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects chronic plaque psoriasis age 18 75 insufficient response topical agent , meet psoriasis assessment expectation define study protocol Females pregnant breastfeed Men woman comply requirement avoid father child become pregnant , respectively Subjects treated leflunomide biological therapy treat psoriasis JAKSTAT inhibitor within 12 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>